Beranda › Gagal Ginjal › Arizona
Uji klinis Gagal Ginjal di Arizona
6 studi untuk Gagal Ginjal mencari peserta di lokasi di Arizona.
Kota di Arizona
Teks studi resmi (Bahasa Inggris)
A Study to Evaluate the Pharmacokinetics and Safety of Golcadomide in Participants With Severe Renal Impairment and End-Stage Renal Disease Compared With Participants With Normal Renal Function
- Arizona Clinical Trials - Chandler, Chandler
Menerima pesertaFase 1Sukarelawan sehat diterima
Usia 18 hingga 84 · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT07763418Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
- AKDHC Medical, Glendale
- Kidney Disease Medical Group, Glendale
- AKDHC Medical, Phoenix
- dan 2 lainnya
Menerima pesertaFase 2/3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 21 Sep 2026 · NCT05485961REgulatory T Cell Therapy to Achieve Immunosuppression REduction
- Mayo Clinic in Arizona, Phoenix
Menerima pesertaFase 2
Usia 18 hingga 65 · Semua jenis kelamin · Diperbarui 27 Apr 2026 · NCT06552169Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial
- Southwest Kidney Institute, Phoenix
- AKDHC Medical Research Services, Phoenix
- AKDHC Center Tucson, Tucson
Menerima peserta
Usia 18 hingga 84 · Semua jenis kelamin · Diperbarui 13 Apr 2026 · NCT06190717SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study
- AKDHC Bullhead City, Bullhead City
- AKDHC Marana Surgery Center, Marana
- Arizona Kidney Disease & Hypertension Centers (AKDHC) Phoenix Surgery Center, Phoenix
- dan 1 lainnya
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Feb 2026 · NCT06001827A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease
- AKDHC Medical Research Services, LLC, Phoenix
Menerima peserta
Usia 18 hingga 90 · Semua jenis kelamin · Diperbarui 22 Des 2025 · NCT04671771Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.